The current COVID‐19 pandemic has created seismic shifts for all of us. With unprecedented pressures on the health service and many staff being moved into different roles and ways of working, a lot of us are finding this a particularly uncertain time.

Most men with prostate cancer understand the risk that COVID‐19 poses to themselves and their healthcare professionals, and they appreciate the rationale behind adjustments to their cancer treatment plans. Understandably though, many are fearful about the implications this has for their prostate cancer, their overall prognosis and their return to normal life.

Specialist nurses at Prostate Cancer UK support the NHS by offering extra information to patients that need it. Recently, they have had to deal with a high increase in the number of calls relating to issues concerning the current COVID‐19 situation, including delays to treatment and concerns over safety

The current pandemic has amplified the anxiety felt by men with prostate cancer and their families. Even under normal circumstances, the specialist nurses at Prostate Cancer UK receive numerous enquiries asking us to clarify to patients what has been explained in clinic and to talk through concerns. While the specialist nurse teams at Prostate Cancer UK cannot offer clinical advice, we support NHS services by offering additional time, information and support to those who need it. Since the start of the COVID‐19 pandemic, there has been a large increase in the volume of calls to the team, with over a third of all calls relating to issues concerning the current COVID‐19 situation. Box [1](#tre747-tbl-0001){ref-type="table"} provides some examples.

###### 

Comments from anonymous Prostate Cancer UK service users

+:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Patient one: 'I called regarding Covid and the impact it\'ll have on me as I have advanced prostate cancer. The nurse was fantastic, she reassured me and talked me through it. What she said made perfect sense. Fantastic.' |
|                                                                                                                                                                                                                               |
| Patient two: 'It was very helpful. It reassured me the consultant is saying the right things at this time when things are being delayed.'                                                                                     |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

![The Specialist Nurse team at Prostate Cancer UK](TRE-11-6-g001){#tre747-fig-0001}

Although it can feel as if day‐to‐day healthcare is struggling to remain standing, Prostate Cancer UK has heard from men expressing huge levels of gratitude for their healthcare teams during this time. We have also been hearing about some of their concerns, most of which are predictable given the situation, while others have been more of a surprise.

Here, we share some of the themes raised by prostate cancer patients from across the UK and some of the things that have helped men feel more supported as they struggle to find solid ground in the uncertain shockwaves created by COVID‐19.

Treatment gaps {#tre747-sec-0002}
==============

Overwhelmingly, recent contacts to the specialist nurses at Prostate Cancer UK have focused on the risk of delays to treatment. While they often acknowledge uncertainties, men want to understand that some form of individualised risk stratification has taken place for them. Some men have contacted us to say they were told about their treatment changes without an explanation of the rationale, leaving them concerned that their best interests were not being considered. In order to help alleviate this concern, it has been our experience that explaining national guidelines have been drawn up, such as those by BAUS or NHS England, has helped men to understand that their risk is being considered.[^1^](#tre747-bib-0001){ref-type="ref"}, [^2^](#tre747-bib-0002){ref-type="ref"}

Men with lower‐risk prostate cancer who have had their surgery delayed sometimes have the impression they are being left with no treatment simply because there is not another option. Letting them know that hormone therapy is available for the men at highest risk from treatment deferral can help to provide context for their situation by reassuring them that they would receive treatment if their cancer was high risk enough to require it (see following section 'New gaps in understanding').

It is important that these alternative treatments are made available when needed. A number of GPs have told men (predominantly those with advanced prostate cancer) that they will not be able to have their hormone therapy injections until 'after the crisis is over'. Understandably, this is extremely concerning for many men and Prostate Cancer UK is encouraging GPs to consider benefits of treatment, while maintaining awareness of the COVID‐19 risks, to enable as many men as possible to continue receiving their hormone treatment in primary care.

Stopping, or not starting, chemotherapy in newly diagnosed men with hormone‐sensitive, metastatic prostate cancer has also caused great concern for patients who worry they may be excluded from this option once the risk from COVID‐19 diminishes. At Prostate Cancer UK we worked with NHS decision makers and clinicians to secure emergency access to enzalutamide, an alternative treatments to chemotherapy with equal survival benefit.

Staffing gaps {#tre747-sec-0003}
=============

With often familiar and trusted members of their healthcare teams being moved away to new duties, many men have been expressing a sense of loss and abandonment -- albeit mingled with understanding, empathy and concern for their 'fantastic' healthcare professionals.

Unfortunately, these new gaps leave many prostate cancer patients unsure about how to navigate the healthcare system or who to contact, particularly if they cannot get a response from their GP surgery. Anxiety is particularly acute in those patients partway along the diagnostic pathway who cannot identify who to speak to about their concerns.

We have also had calls from men and their families who are incredibly mindful of not wanting to put any pressure on NHS staff, or 'waste anyone\'s time', but who actually need medical help. This includes men in acute pain following biopsy or surgery, who were subsequently found to have infection.

Where possible, the certainty of a central point of contact with their hospital team is offering great reassurance to men and their families, especially if they have just been given a diagnosis or had recent treatment. Similarly, our experience shows that men are very grateful to be offered telephone or video conversations *in lieu* of face‐to‐face clinics. Unfortunately, there is not a single NHS system set up to facilitate this and hospitals are establishing their own solutions.

New gaps in understanding {#tre747-sec-0004}
=========================

We have spoken to men who have been put on hormone therapy because their radical treatment has been delayed, but who do not understand that hormone therapy is an effective treatment for prostate cancer. This includes some men scheduled to have radiotherapy who are unaware that hormone therapy would be a part of their standard treatment. Consequently, they feel they are being 'palmed off' or placated by the treatment.

In our experience some men and families feel that the treatment of COVID‐19 patients is being given higher priority over cancer treatment, but they do not understand why. This is generating some anger, but we have found that by taking the time to explain the situation, this tends to dissipate quickly. As mentioned, we are unable to advise on the clinical implications for individuals, and the clear position from NHS England is that if cancer patients are worried about their situation they should talk to their clinical team. This makes the personalised contact that we have mentioned above critical.

Planning to rebuild {#tre747-sec-0005}
===================

As the peak of the crisis passes, we need to rebuild NHS teams and cancer pathways while COVID‐19 still poses an ongoing threat.

One concern is that men with prostate cancer will continue to be considered vulnerable (as they are often older and have comorbidities) but will not be made a priority in the post‐peak landscape because prostate cancer is typically viewed as not as aggressive as other cancers. With a creeping narrative emerging that men with prostate cancer are too vulnerable to treat in normal clinics, but are not urgent enough for specialised care, we need to ensure these men are not forgotten. This 'broad brush' approach raises the real risk that men will slip through the net who would otherwise have had their cancer successfully treated, or their lives significantly extended.

However, the COVID‐19 crisis has also created a unique opportunity. Redesigning healthcare systems has been compared to rebuilding an aeroplane mid‐flight, but COVID‐19 has forced some clinics to suspend all normal prostate cancer diagnosis and treatment, effectively forcing an emergency landing of that plane. This can create the space to think afresh about how men\'s needs can be met and good practice care can best be delivered in the future. For example, thinking about how clinic lists can be structured to facilitate greater multidisciplinary input for patients with advanced disease.

Due to the enforced distancing rules, healthcare professionals are also experiencing new ways of running clinics. Besides avoiding the viral risk, this helps patients avoid costly car parks, transport costs and long waits in crowded rooms for routine follow‐up appointments that often last only a few minutes. The legacy of this should be greater adoption of evidence‐based and risk stratified personalised follow‐up pathways, with proper safety nets in place to ensure that no man is forgotten, such as the TrueNORTH Supported Self‐Management programme.[^3^](#tre747-bib-0003){ref-type="ref"}

In regard to safety‐netting, the most urgent task facing teams will be the triaging of patients who have had their diagnosis or treatment deferred, to ensure that patients who are most at risk have urgent access to life saving or life extending treatments.

Summary {#tre747-sec-0006}
=======

We know that the journey back to any sense of 'normality' is likely to be long. While the vast majority of men we speak to understand that these are exceptionally challenging times, we have found that communicating clearly with patients about why decisions have been made about their care can make all the difference. This may be even more true as we move out of the acute phase of the pandemic and patients (as well as the health care professionals who treat them) need to know that there is a plan to rebuild.

As we begin this process, it is increasingly important that men with prostate cancer are not forgotten or deprioritised. This is particularly true of those men with high‐risk disease whose treatment has been delayed, or men at risk of cancer recurrence or progression who cannot afford to wait until long after this crisis is over to receive their treatment.

More information {#tre747-sec-0007}
================

Prostate Cancer UK has a website page dedicated to information about prostate cancer and COVID‐19.[^4^](#tre747-bib-0004){ref-type="ref"}

Men and their clinicians can also contact Prostate Cancer UK\'s Specialist Nurses on 0800 074 8383 or online via the live chat instant messaging service: [www.prostatecanceruk.org](http://www.prostatecanceruk.org) (available 9am to 6pm Monday to Friday, except Wednesdays when it is open 10am to 8pm).
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